Related Experiment Video
Updated: May 15, 2026

Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Everolimus causing severe hypertriglyceridemia and acute pancreatitis.
Somasundaram Subramaniam1, Jason A Zell, Pamela L Kunz
1Stanford Cancer Institute, Stanford, California, USA.
Everolimus, an mTOR inhibitor, can cause severe hypertriglyceridemia and pancreatitis in patients with metastatic pancreatic neuroendocrine tumors (pNETs). Monitoring and management strategies allow continued treatment.
Area of Science:
- Oncology
- Pharmacology
- Endocrinology
Background:
- Everolimus is an mTOR inhibitor used for metastatic pancreatic neuroendocrine tumors (pNETs), renal cell carcinoma, and posttransplant immunosuppression.
- Hypertriglyceridemia and acute pancreatitis are potential serious side effects of everolimus therapy.
Related Concept Videos
Acute Pancreatitis I: Introduction
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute Pancreatitis II: Pathophysiology
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Chronic Pancreatitis II: Pathophysiology

